Deals
Aspen Faces EU Antitrust Probe Over Pricing of Cancer Drugs
- EU takes first case over pharmaceutical firms’ price increases
- Aspen was fined 5 million euros in Italy for 1,500% price hike
This article is for subscribers only.
Aspen Pharmacare Holdings Ltd. faces a European Union antitrust probe for ramping up the price of cancer drugs as the EU joins a global crackdown on the soaring cost of life-saving generic medicines.
"When the price of a drug suddenly goes up by several hundred percent, this is something the commission may look at," EU Competition Commissioner Margrethe Vestager said in an emailed statement on Monday.